Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments

Abstract

We reported previously the development of SMFv-PE38K-

The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes

“…These results firmly demonstrated that anti-EGFR Fab' conjugation could specifically enhance the binding affinity of TLPD-FCC in breast cancer cells of high or moderate EGFR expression, but not in cells with low EGFR expression. These results were consistent with our previous results about the in vitro targeting efficiency of targeted nanoparticles in hepatocellular carcinoma cell lines with different tumor specific antigen expression [24].…”

Lyophilized HER2-specific PEGylated immunoliposomes for active siRNA gene silencing

“…Proliferation of SK-BR3 and MCF-7 cells was measured by Cell Titer 96 nonradioactive cell proliferation assay kit according to the manufacturer's protocols (Promega, Madison, WI) as described before [22]. Briefly, the cells were seeded into 96-well plates (3 Â 10 4 cells per well) and incubated overnight.…”

Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma

“…Gao et al also developed PE38KDEL type I mutant-loaded PLGA NPs conjugated with SM5-1 mAb F(ab'). 147 The results showed that the NPs were specifically internalized into Ch-hep-3 cells with high efficiency and exhibited potent cytotoxicity of hepatoma cells.…”